


**REMARKS**

In the amendment, the Applicant has amended the specification to reflect the fact that this application is a national phase of the international application. In addition, the Applicant has cancelled without prejudice original claims 1-19 and added new claims 20-38, respectively. The wording of the new claims corresponds to the amendments to the claims effected during prosecution of the international application. In addition, the Applicant has revised the multiple dependencies of the claims to eliminate the improper multiple dependencies and to reduce the PTO filing fee.

Favorable action on the merits is solicited.

Respectfully submitted,

Martin Hermann Klemens BRUNE et al.

By   
Warren M. Cheek, Jr.  
Registration No. 33,367  
Attorney for Applicants

WMC/dlk  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
September 25, 2001

09937296:111401

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Martin Hermann Klemens BRUNE et al.

Group Art Unit 1652

Serial No. 09/937,296

Examiner D. Steadman

Filed November 14, 2001

Confirmation No. 9738

ASSAYS FOR NUCLEOSIDE DIPHOSPHATES  
AND TRIPHOSPHATES

AMENDMENT

Assistant Commissioner for Patents,  
Washington, DC 20231

Sir:

Responsive to the Official Action dated June 24, 2002, the time for responding thereto being extended for one month in accordance with a petition for extension submitted concurrently herewith, please amend the above-identified application as follows:

IN THE CLAIMS

Cancel without prejudice claims 22 and 23.

Please amend the claims as follows:

20. <sup>twice</sup> (Amended) A process for detecting the presence of a nucleoside diphosphate in a sample, comprising a step of detecting the dephosphorylation of the phosphoenzyme form of a nucleoside diphosphate kinase (NDPK), wherein the NDPK is modified to carry a label in both <sup>an extrinsic</sup> its phosphorylated and unphosphorylated forms, which label gives a different detectable signal when the enzyme is phosphorylated from when it is unphosphorylated.
21. <sup>twice</sup> (Amended) A process for detecting the presence of a nucleoside triphosphate in a sample, comprising a step of detecting the phosphorylation of a nucleoside diphosphate kinase (NDPK) to the phosphoenzyme form, wherein the NDPK is modified to carry a label in both <sup>an extrinsic</sup> its <sup>the NDPK's</sup>

phosphorylated and unphosphorylated forms, which label gives a different detectable signal when the enzyme is phosphorylated from when it is unphosphorylated.

24. (Amended) The process of claim 20 or claim 21, wherein the NDPK carries a fluorescent label.

31. (Amended) <sup>Twice</sup> NDPK which is modified to carry <sup>an extrinsic</sup> a label in both <sup>the NDPK's</sup> its phosphorylated and unphosphorylated forms, which label gives a different detectable signal when the enzyme is phosphorylated from when it is unphosphorylated.

(Amended)

30. <sup>an</sup> The process of claim 20 or claim 21, wherein the NDPK is the NDPK of <sup>having the amino acid sequence of SEQ ID No. 2</sup> *Myxococcus xanthus* ~~carrying a Asp112-Cys mutation~~, and carrying an IDCC label at <sup>position 112</sup> ~~this~~ mutated residue.

31. NDPK is modified to carry a label which gives a different detectable signal when the enzyme is phosphorylated from when it is unphosphorylated.

32. The NDPK of claim 31, wherein the label on the modified NDPK is a fluorescent label.

33. The NDPK of claim 32, wherein the fluorescent label is attached to the NDPK via a cysteine residue.

34. The NDPK of claim 32 or claim 33, wherein the fluorescent label is IDCC.

(Amended) <sup>having the amino acid sequence of SEQ ID No. 2</sup>  
35. NDPK of *Myxococcus xanthus* ~~carrying a Asp112-Cys mutation~~, and carrying an IDCC label at ~~this mutated residue~~ <sup>position 112</sup>.

36. NDPK modified by the attachment of at least one detectable label that is sensitive to the binding of a nucleoside diphosphate.

37. A substrate having the NDPK of any one of claims 31, 35 or 36 immobilised thereto.

38. The NDPK of any one of claims 31, 35 or 36 for use as an *in vivo* or *in vitro* diagnostic reagent.